Protein Therapeutics Market: Size, Share, Trends & Forecast (2024-2029)

The market report presents a thorough analysis segmented by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone); by Application (Metabolic Disorder, Immunologic Disorders, Hematological Disorder, Cancer, Hormonal Disorder, Genetic Disorder, Others); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa). 

Outlook 

• The protein therapeutics market is estimated to be at USD 383.85 Bn in 2024 and is anticipated to reach USD 531.56 Bn in 2029. 

• The protein therapeutics market is registering a CAGR of 6.73% during the forecast period of 2024-2029. 

• The protein therapeutics market is experiencing robust growth driven by advancements in biotechnology, rising chronic disease prevalence, and increased R&D investments. Major pharmaceutical players and biotech startups are competing intensely, with a focus on innovative treatments and biosimilars. 

Request a free sample. 

Ecosystem  

• The participants in the global protein therapeutics industry are always developing their strategies to preserve a competitive advantage.  

• Innovative biotech startups are entering the market with advanced protein therapeutics, challenging traditional pharma companies. Firms like Moderna and BioNTech are rapidly gaining prominence with their mRNA-based therapies. 

• Several important entities in the protein therapeutics market include Pfizer Inc.; Amgen Inc.; Novo Nordisk A/S; Abbott Laboratories; Johnson & Johnson; and others. 

Ask for customization. 

Findings 

Attributes	Values
Historical Period	2018-2022
Base Year	2023
Forecast Period	2024-2029
Market Size (2024)	USD 383.85 Bn
Market Size (2029)	USD 531.56 Bn
Growth Rate	6.73% CAGR from 2024 to 2029
Key Segments	Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone); Application (Metabolic Disorder, Immunologic Disorders, Hematological Disorder, Cancer, Hormonal Disorder, Genetic Disorder, Others); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa)
Key Vendors	Pfizer Inc.; Amgen Inc.; Novo Nordisk A/S; Abbott Laboratories; Johnson & Johnson
Key Countries	The U.S; Canada; Mexico; Brazil; Argentina; Colombia; Chile; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa
Largest Market	North America

Get a free quote. 

Trends  

• Personalized Medicine: There’s a growing focus on developing protein therapeutics tailored to individual patients. Companies like Amgen are using genetic profiling to create customized treatments for cancer, offering more effective and targeted therapies. 

• Expanding Therapeutic Areas: Protein therapeutics are increasingly being applied to new therapeutic areas beyond traditional oncology and autoimmune diseases. Vertex Pharmaceuticals is exploring protein-based treatments for cystic fibrosis, offering new hope for rare disease patients. 

• Development of Next- Generation Protein Therapeutics: Clustered Regularly Interspaced Short Palindromic Repeats CRISPR and other gene-editing technologies are enabling the development of next-generation protein therapeutics. Companies like Editas Medicine are leveraging CRISPR to create novel therapies that can edit disease-causing genes at the protein level. 

Speak to analyst. 

Catalysts 

• Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases like diabetes and cancer is driving demand for protein therapeutics. For instance, insulin therapies by companies like Novo Nordisk are in higher demand due to the global diabetes epidemic. 

• Government Support and Funding: Government initiatives and funding for biopharmaceutical research are bolstering the protein therapeutics market. The U.S. FDA’s expedited approval processes for orphan drugs encourage companies like Biogen to develop rare disease therapies. 

• Aging Population: The global aging population is increasing the need for protein therapeutics, especially in age-related conditions. Companies like Genentech are expanding their portfolios to address conditions such as Alzheimer’s and osteoporosis. 

Inquire before buying. 

Restraints 

• High Development Costs: The development of protein therapeutics is expensive and time-consuming, often requiring large investments with uncertain returns. For example, the high costs associated with clinical trials can be a barrier for smaller biotech firms. 

• Biosimilar Competition: The rise of biosimilars is increasing competition and driving down prices, affecting profit margins for original biologics. For instance, AbbVie’s Humira is facing stiff competition from multiple biosimilar versions, leading to a loss in market share. 

• Limited Patient Access: High costs and complex distribution channels often limit patient access to protein therapeutics, particularly in developing regions. Companies like Gilead are working on strategies to improve access but face significant challenges in market penetration. 

Personalize this research. 

Hotspot 

Explore purchase options. 

Table of Contents 

1.       Introduction         1.1.    Research Methodology         1.2.    Scope of the Study  2.       Market Overview / Executive Summary         2.1.    Global Protein Therapeutics Market (2018 – 2022)         2.2.    Global Protein Therapeutics Market (2023 – 2029)  3.       Market Segmentation         3.1.    Global Protein Therapeutics Market by Product                3.1.1.    Monoclonal Antibodies                3.1.2.    Insulin                3.1.3.    Fusion Protein                3.1.4.    Erythropoietin                3.1.5.    Interferon                3.1.6.    Human Growth Hormone                3.1.7.    Follicle Stimulating Hormone         3.2.    Global Protein Therapeutics Market by Application                3.2.1.    Metabolic Disorder                3.2.2.    Immunologic Disorders                3.2.3.    Haematological Disorder                3.2.4.    Cancer                3.2.5.    Hormonal Disorder                3.2.6.    Genetic Disorder                3.2.7.    Others  4.       Regional Segmentation         4.1.    North America                4.1.1.    The US                4.1.2.    Canada                4.1.3.    Mexico         4.2.    South America                4.2.1.    Brazil                4.2.2.    Argentina                4.2.3.    Colombia                4.2.4.    Chile                4.2.5.    Rest of South America         4.3.    Asia Pacific                4.3.1.    China                4.3.2.    India                4.3.3.    Japan                4.3.4.    South Korea                4.3.5.    Rest of Asia Pacific         4.4.    Europe                4.4.1.    The UK                 4.4.2.    Germany                4.4.3.    Italy                4.4.4.    France                4.4.5.    Spain                4.4.6.    Rest of Europe         4.5.    The Middle East                4.5.1.    Turkey                4.5.2.    UAE                4.5.3.    Saudi Arabia                4.5.4.    Rest of the Middle East         4.6.    Africa                4.6.1.    Egypt                4.6.2.    South Africa                4.6.3.    Rest of Africa  5.       Value Chain Analysis of the Global Protein Therapeutics Market  6.       Porter Five Forces Analysis         6.1.    Threats of New Entrants         6.2.    Threats of Substitutes         6.3.    Bargaining Power of Buyers         6.4.    Bargaining Power of Suppliers         6.5.    Competition in the Industry  7.       Trends, Drivers and Challenges Analysis         7.1.    Market Trends         7.1.1.    Market Trend 1         7.1.2.    Market Trend 2         7.1.3.    Market Trend 3         7.2.    Market Drivers         7.2.1.    Market Driver 1         7.2.2.    Market Driver 2         7.2.3.    Market Driver 3         7.3.    Market Challenges         7.3.1.    Market Challenge 1         7.3.2.    Market Challenge 2         7.3.3.    Market Challenge 3  8.       Opportunities Analysis         8.1.    Market Opportunity 1         8.2.    Market Opportunity 2         8.3.    Market Opportunity 3  9.       Competitive Landscape         9.1.    Pfizer Inc.         9.2.    Amgen Inc.         9.3.    Novo Nordisk A/S          9.4.    Abbott Laboratories         9.5.    Johnson & Johnson         9.6.    Company 6         9.7.    Company 7         9.8.    Company 8         9.9.    Company 9         9.10.  Company 10

Know the research methodology. 

Protein Therapeutics Market – FAQs 

1.  What is the current size of the protein therapeutics market? 

Ans. In 2024, the protein therapeutics market size is $383.85 Bn. 

2.  Who are the major vendors in the protein therapeutics market?  

Ans. The major vendors in the protein therapeutics market are Pfizer Inc.; Amgen Inc.; Novo Nordisk A/S; Abbott Laboratories; Johnson & Johnson. 

3.  Which segments are covered under the protein therapeutics market segments analysis?  

Ans. The protein therapeutics market report offers in-depth insights into Product, Application, and Geography.